TGFβ is a master regulator of radiation therapy-induced antitumor immunity

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2232-2242

  Vanpouille Box, Claire ^a   Diamond, Julie M ^a   Pilones, Karsten A ^a   Zavadil, Jiri ^a   Babb, James S ^a   Formenti, Silvia C ^a   Barcellos Hoff, Mary Helen ^a   Demaria, Sandra ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; MONOCLONAL ANTIBODY RMP1 14; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER CELL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR REJECTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION RESPONSE; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASM RECURRENCE, LOCAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84929366910     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3511     Document Type: Article

References (50)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23.
2. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369: 134-44.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-54.
4. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: Are we there yet? Immunol Rev 2011;239: 27-44.
5. Formenti SC, Demaria S. Radiotherapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012;84: 879-80.
6. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174: 7516-23.
7. + T cells: Changing strategies for cancer treatment. Blood 2009;114: 589-95.
8. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008;181: 3099-107.
9. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008;180: 3132-9.
10. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170: 6338-47.
11. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiationmodulates the peptide repertoire, enhancesMHCclass I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203: 1259-71.
12. Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves anti-tumor effects. J Clin Invest 2012;122: 3718-30.
13. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, et al. Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Semin Immunol 2010;22: 113-24.
14. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type i interferondependent innate and adaptive immunity. Cancer Res 2011;71: 2488-96.
15. Demaria S, Ng B, Devitt M-L, Babb JS, KawashimaN, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58: 862-70.
16. Demaria S, Kawashima N, Yang AM, Devitt M-L, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases following treatmentwith local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11: 728-34.
17. Dewan MZ, Galloway AE, KawashimaN, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15: 5379-88.
18. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10: 718-26.
19. Barcellos-Hoff MH, Cucinotta FA. New tricks for an old fox: Impact of TGFbeta on the DNA damage response and genomic stability. Sci Signal 2014;7: Re5.
20. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994;93: 892-9.
21. Jobling MF, Mott JD, Finnegan MT, Jurukovski V, Erickson AC, Walian PJ, et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res 2006;166: 839-48.
22. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, et al. TGFb1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 2011;17: 6754-65.
23. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: Implications for anticancer therapy. Clin Cancer Res 2007;13: 5262-70.
24. Aslakson CJ, Miller FR. Selective events in themetastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52: 1399-405.
25. Rosato A, Santa SD, Zoso A, Giacomelli S, Milan G, Macino B, et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res 2003;63: 2158-63.
26. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 1989;142: 1536-41.
27. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 2011;35: 123-34.
28. Siegel S, Wagner A, Schmitz N, ZeisM. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 2003;122: 911-4.
29. Demaria S, Wang B, Yang AM, Santori F, Kawashima N, Matsumura S. Immunotherapy against metastatic breast cancer with a twist Breast Cancer Res Treat 2007;106: S31-S31.
30. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19: 185-93.
31. Pavlidis P, Noble WS. Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol 2001;2: RESEARCH0042.
32. + T cells via dendritic cell activation. J Immunol 2012;189: 558-66.
33. + T cell tolerance and permits effective immunity. Immunity 2008;29: 934-46.
34. Nam JS, TerabeM, MamuraM, KangMJ, Chae H, Stuelten C, et al. An antitransforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008;68: 3835-43.
35. Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-b. Cancer Res 2012;72: 4119-29.
36. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012;131: 387-95.
37. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Murtas D, et al. An immunologic portrait of cancer. J Transl Med 2011; 9: 146.
38. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008;29: 256-62.
39. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24: 207-12.
40. + tumor-reactive repertoire infiltratinghuman tumors. J Clin Invest 2014;124: 2246-59.
41. Postow MA, Callahan MK, Wolchok JD. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Clin Cancer Res 2012;18: 1821-3.
42. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32: 1020-30.
43. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: A revived partnership. Int J RadiatOncol Biol Phys 2005;63: 655-66.
44. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: A synergistic combination. J Clin Invest 2013;123: 2756-63.
45. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 2013;105: 256-65.
46. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14: 1014-22.
47. Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, et al. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 2008;14: 4883-90.
48. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, amaster regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117: 927-39.
49. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4: 127ra37.
50. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515: 577-81.